Guido Lancman, MD | Authors

January 11, 2021

Hypogammaglobulinemia was found to be nearly universal for patients with multiple myeloma during treatment with daratumumab, suggesting a role for intravenous immunoglobulin.

January 08, 2021

A study of the use of intravenous immunoglobulin on infections in patients with multiple myeloma receiving daratumumab suggested a role for the strategy in this patient population.

December 31, 2020

Guido Lancman, MD, sought to evaluate the effect of intravenous immunoglobulin on infections in patients with multiple myeloma receiving daratumumab.

December 26, 2020

A study of the effect of intravenous immunoglobulin (IVIG) on infections in patients with multiple myeloma receiving daratumumab indicated that hypogammaglobulinemia was nearly universal during treatment, suggesting a role for IVIG.

December 17, 2020

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed which patient groups he believes require more attention.

December 13, 2020

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai highlighted multiple myeloma treatments that he believes have shown promise over the past year.

December 10, 2020

The hematology and oncology fellow at the Icahn School of Medicine at Mount Sinai discussed exciting treatment options for patients with multiple myeloma that are being presented at ASH this year.